English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Immunotherapy of Patients With Hormone-Refractory Prostate Carcinoma Pre-Treated With Interferon-Gamma and Vaccinated With Autologous PSA-Peptide Loaded Dendritic Cells--A Pilot Study

MPS-Authors
/persons/resource/persons191059

Freudenberg,  M. A.
Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

/persons/resource/persons191247

Niedermann,  G.
Emeritus Group: Cellular Immunology, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Hildenbrand, B., Sauer, B., Kalis, O., Stoll, C., Freudenberg, M. A., Niedermann, G., et al. (2007). Immunotherapy of Patients With Hormone-Refractory Prostate Carcinoma Pre-Treated With Interferon-Gamma and Vaccinated With Autologous PSA-Peptide Loaded Dendritic Cells--A Pilot Study. The Prostrate, 67, 500-508.


Cite as: https://hdl.handle.net/11858/00-001M-0000-002B-91BF-4
Abstract
PURPOSE: We conducted a pilot trial to assess the feasibility and tolerability of a prime/boost vaccine strategy using interferon-gamma (IFN-γ) and autologous dendritic cells (DCs) pulsed with HLA-A2-specific prostate-specific antigen (PSA) peptides (PSA-1 [141-150]; PSA-2 [146-156]; PSA-3 [154-163]) for the treatment of 12 patients with hormone refractory prostate carcinoma. PATIENTS AND METHODS: All patients were vaccinated four times with intracutaneously injected PSA-peptide loaded DCs after subcutaneous administration of IFN-γ 2 hr before DC administration (50 μg/m2 body surface). Objectives were safety, clinical benefit, clinical and biochemical response, quality of life, and immunological parameters. RESULTS: The vaccination was well tolerated without any vaccination-associated adverse events. One partial and one mixed responder were identified, four patients showed stable diseases. Two patients had a decrease and four a slow-down velocity slope in the PSA serum level. All responders showed a positive DTH-response, but only two a slight increase in PSA-peptide specific T-lymphocytes. CONCLUSION: The immunotherapy with IFN-γ and PSA-peptide loaded DCs was feasible and well tolerated. The observed responses imply a potential antitumor activity.